Overview
On 28 January 2010, orphan designation (EU/3/09/702) was granted by the European Commission to Dafra Pharma International NV, Belgium, for beta-artemether / lumefantrine (powder for oral suspension) for the treatment of malaria.
Key facts
Active substance |
|
Intended use |
Treatment of malaria
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/09/702
|
Date of designation |
28/01/2010
|
Sponsor |
Dafra Pharma International NV
Slachthuisstraat 30/7 2300 Turnhout Belgium Telephone: +32 14 61 78 20 Telefax: +32 14 61 78 59 E-mail: info@dafra.be |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: